Vanguard Portfolio Management
ADPT icon

Vanguard Portfolio Management’s Adaptive Biotechnologies ADPT Stock Holding History

Vanguard Portfolio Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117M Buy
5,476,231
+984,757
+22% +$15.1M 0.01% 1446
2026
Q1 		$62.3M Buy
+4,491,474
New +$71.6M ﹤0.01% 1604

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Portfolio Management's ADPT Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Adaptive Biotechnologies (ADPT) stake by 22% in Q2 2026, buying an estimated $15.1M and bringing the position to 5,476,231 shares worth $117M. The position accounts for 0.01% of the portfolio, ranked #1446.

Vanguard Portfolio Management first reported a position in ADPT in Q1 2026 and has held it in 2 quarters since. 299 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Vanguard Portfolio Management held 5,476,231 shares of Adaptive Biotechnologies worth $117M as of Q2 2026.
  • Vanguard Portfolio Management bought 984,757 Adaptive Biotechnologies shares in Q2 2026, an estimated $15.1M.
  • Adaptive Biotechnologies made up 0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1446 holding.
  • Vanguard Portfolio Management first reported a position in Adaptive Biotechnologies in Q1 2026 and has held it in 2 quarters since.
  • 299 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.